The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus

Robert A Vigersky, Robert A Vigersky

Abstract

Hypoglycemia mitigation is critical for appropriately managing patients with diabetes. Advanced technologies are becoming more prevalent in diabetes management, but their benefits have been primarily judged on the basis of hemoglobin A1c. A critical appraisal of the effectiveness and limitations of advanced technologies in reducing both A1c and hypoglycemia rates has not been previously performed. The cost of hypoglycemia was estimated using literature rates of hypoglycemia events resulting in hospitalizations. A literature search was conducted on the effect on A1c and hypoglycemia of advanced technologies. The cost-effectiveness of continuous subcutaneous insulin infusion (CSII) and real-time continuous glucose monitors (RT-CGM) was reviewed. Severe hypoglycemia in insulin-using patients with diabetes costs $4.9-$12.7 billion. CSII reduces A1c in some but not all studies. CSII improves hypoglycemia in patients with high baseline rates. Bolus calculators improve A1c and improve the fear of hypoglycemia but not hypoglycemia rates. RT-CGM alone and when combined with CSII improve A1c with a neutral effect on hypoglycemia rates. Low-glucose threshold suspend systems reduce hypoglycemia with a neutral effect on A1c, and low-glucose predictive suspend systems reduce hypoglycemia with a small increase in plasma glucose levels. In short-term studies, artificial pancreas systems reduce both hypoglycemia rates and plasma glucose levels. CSII and RT-CGM are cost-effective technologies, but their wide adoption is limited by cost, psychosocial, and educational factors. Most currently available technologies improve A1c with a neutral or improved rate of hypoglycemia. Advanced technologies appear to be cost-effective in diabetes management, especially when including the underlying cost of hypoglycemia.

Conflict of interest statement

Declaration of Conflicting Interests: The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Combined effect of real-time continuous glucose monitoring on changes in A1c and hypoglycemia rates. Source: Liebl et al.

References

    1. Rosenthal E. Even small medical advances can mean big jumps in bills. New York Times. April 5, 2014. Available at: . Accessed September 23, 2014.
    1. Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 174:678-86, 2014
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med. 1993;329:977-986.
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med. 2005;353:2643-2653.
    1. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes. 1997;46:271-276.
    1. Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D exchange clinic registry. J Clin Endo Metab. 2013;98:3411-3419.
    1. Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes. Diabetes Care. 2013;36:3535-3542.
    1. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endo Metab. 2013;98:1845-1859.
    1. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;36(suppl 1):S14-S80.
    1. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med. 2008:25:501-504.
    1. Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin Pract. 2010;87:64-68.
    1. Choudhary P, Geddes J, Freeman JV, Emery CJ, Heller SR, Frier BM. Frequency of biochemical hypoglycaemia in adults with type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. Diabet Med. 2010;27:666-672.
    1. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20:1016-1021.
    1. Leiter Al, Yale FJ, Chiasson JL, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes in glycemic and hypoglycemia management. Can J Diabetes. 2005; 29:186-192.
    1. Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care. 2011;17:673-680.
    1. Brod M, Wolden M, Christensen T, Bushnell DM. Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization. Value Health. 2013;16:1140-1140.
    1. Cavanaugh K, Huizinga MM, Wallston KA, et al. Association of numeracy and diabetes control. Ann Int Med. 2008;148:737-746.
    1. Sussman A, Taylor EJ, Patel M, et al. Performance of a glucose meter with a built-in automated bolus calculator versus manual bolus calculation in insulin-using subjects. J Diabetes Sci Technol. 2012;6:330-344.
    1. Diabetes In Control. Updated bolus calculators for diabetes management. Issue 721, March 20, 2014. Available at: . Accessed October 2014.
    1. Schmidt S, Norgaard K. Bolus calculators. J Diabetes Sci Technol. 2014;8:1035-1041.
    1. Garg SK, Bookout TR, McFann KK, et al. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technol Ther. 2008;10:369-375.
    1. Ramotowska A, Golicki D, Dzygalo K, Szypowska A. The effect of using the insulin pump bolus calculator compared to standard insulin dosage calculations in patients with type 1 diabetes mellitus—a systematic review. Exp Clin Endocrinol Diabetes. 2013;121:248-254.
    1. Barnard K, Parkin C, Young A, Ashraf M. Use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in patients with type 1 diabetes mellitus treated with multiple daily insulin injections. J Diabetes Sci Technol. 2012;6:144-149.
    1. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765-774.
    1. Golden SH, Brown T, Yeh HC, et al. Methods for insulin delivery and glucose monitoring: comparative effectiveness. Comparative Effectiveness Review 57, AHRQ Publication 12-EHC036-EF. Rockville, MD: Agency for Healthcare Research and Quality; July 2012. Available at: .
    1. Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, Montori VM. Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab. 2009;94(3):729-740.
    1. Pickup J. The evidence base for diabetes technology: appropriate and inappropriate meta-analysis. J Diabetes Sci Technol. 2013;7:1567-1574.
    1. Frias JP, Bode BW, Bailey TS, Kipnes, Brunelle R, Edelman SV. A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections. J Diabetes Sci Technol. 2011;5:887-893.
    1. Walsh J, Roberts R. Pumping Insulin. 5th ed. San Diego, CA: Torrey Pines Press; 2012.
    1. Lin MH, Connor CG, Ruedy KJ, et al. Race, socioeconomic status, and treatment center are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes. Diabetes Technol Ther. 2013;15:929-934.
    1. Klingensmith GJ, Miller KM, Beck RW, et al. Racial disparities in insulin pump therapy and hemoglobin A1c among T1D exchange participants. Diabetes. 2012;61(suppl 1):A358.
    1. Icks A, Razum O, Rosenbauer J, et al. Lower frequency of insulin pump treatment in children and adolescents of Turkish background with type 1 diabetes: analysis of 21,497 patients in Germany. Diabetes Technol Ther. 2012;14:1105-1109.
    1. Scuffi C, Lucarelli F, Valgimigli F. Minimizing the impact of time lag variability on accuracy evaluation of continuous glucose monitoring systems. J Diabetes Sci Technol. 2012;6:1383-1391.
    1. Floyd B, Chandra P, Hall S, et al. Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus J Diabetes Sci Technol. 2012;6:1094-1102.
    1. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007;9:203-210.
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Beck RW, Hirsch IB, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009;32:1378-1383.
    1. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34:795-800.
    1. Liebl A, Henrichs HR, Heinemann L, et al. Continuous glucose monitoring: evidence and consensus statement for clinical use. J Diabetes Sci Technol. 2013;7:500-519.
    1. Choudhary P, Ramasamy S, Green L, et al. Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care. 2013;36:4160-4162.
    1. Chico A, Vidal-Rios P, Subira M, Novials The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurement for improving metabolic control. Diabetes Care. 2003;26:1153-1157.
    1. Zick R, Petersen B, Richter M, Haug C, SAFIR Study Group. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther. 2007;9:483-492.
    1. Yoo HJ. RT-CGM as a motivational tool for poorly controlled type 2. Diabetes Res Clin Pract. 2008;82:73-79.
    1. Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29:44-50.
    1. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2012;35:32-38.
    1. Diabetes Research in Children Network (DirecNet) Study Group, Buckingham B, Beck RW, et al. Continuous glucose monitoring in children with type 1 diabetes. J Pediatr. 2007;15:388-393.
    1. Danne T, de Valk HW, Kracht T, et al. Reducing glycaemic variability in type 1 diabetes self-management with a continuous glucose monitoring system based on wired enzyme technology. Diabetologia. 2009;52:1496-1503.
    1. Diabetes Research in Children Network Study Group, Weinzimer S, Xing D, et al. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy. Pediatr Diabetes. 2009;10:91-96.
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464-1476.
    1. Wong JC, Foster NC, Maahs DM, et al. Real-time continuous glucose monitoring among participants in the T1D Exchange Clinic Registry. Diabetes Care. 2014;37:2702-2709.
    1. Li R, Barker LE, Shrestha S, et al. Changes over time in high out-of-pocket health care burden in U.S. adults with diabetes 2001-2011. Diabetes Care. 2014;37:1620-1635.
    1. Ramchandani N, Arya S, Ten S, Bhandari S. Real-life utilization of real-time continuous glucose monitoring: the complete picture. J Diabetes Sci Technol. 2011;5:860-870.
    1. Bergenstal R, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Eng J Med. 2010;363:311-320.
    1. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia N Eng J Med. 2013;369:224-232.
    1. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes. JAMA. 2013;310:1240-1247.
    1. Maahs DM, Calhoun P, Buckingham BA, et al. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2014;37:1885-1991.
    1. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473-1478.
    1. Beck RW, Raghinaru D, Wadwa RP, et al. Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system. Diabetes Care. 2014;37:1224-1229.
    1. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Eng J Med. 2013;368:824-833.
    1. Leelarathna L, Dellweg S, Mader JK, et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care. 2014;37:1931-1937.
    1. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Eng J Med. 2014;371:313-325.
    1. Braithwaite RS, Meltzer DO, King JT, Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349-356.
    1. Baltussen RM, Adam T, Tan Torres T, et al. Generalized Cost-Effectiveness Analysis: A Guide. Global Programme on Evidence for Health Policy. Geneva, Switzerland: World Health Organization; 2002.
    1. Grunberger G, Abelseth JM, Bailey TS, et al. Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endo Pract. 2014;20:463-489.
    1. Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. Value Health. 2012;15:632-638.
    1. Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Techno Ther. 2010;12:249-255.
    1. David G, Shafiroff J, Saulnier A, Gunnarsson C. Multiple daily injection therapy (MDI) versus durable insulin pump therapy in type II diabetics: a breakeven analysis. Value Health. 2012;15:A65.
    1. Huang ES, O’Grady M, Basu A, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2010;33:1269-1274.
    1. McQueen RB, Ellis SL, Campbell JD, Nair KV, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc. 2011;9:13.
    1. Ly TT, Brnabic AJM, Eggleston A, et al. Cost-effectiveness of sensor-augmented insulin pump and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health. 2014;17:561-569.
    1. Graham C, Bowman L, Lewis J, Murphy B. Decision analytic model: cost implications of RT-CGM use in insulin requiring patients with hypoglycemic unawareness. Paper presented at: 7th International Conference on Advanced Technologies and Treatments for Diabetes; February 2014; Vienna, Austria.
    1. Fonda SJ, Graham C, Samyshkin Y, Munakata J, Powers J, Price D, Vigersky RA. Cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes (T2DM). Submitted for publication.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa